Xanomeline-Trospium
Cobenfy
Muscarinic M1/M4 Agonist + Peripheral Antagonist
Xanomeline is a selective muscarinic agonist with preferential affinity for M1 and M4 receptors in the central nervous system, producing antipsychotic efficacy through a non-dopaminergic mechanism. This is the first and only non-dopaminergic antipsychotic approved by the FDA. Trospium is a quaternary ammonium muscarinic antagonist that does not cross the blood-brain barrier, functioning as a peripheral muscarinic antagonist to mitigate cholinergic side effects (particularly GI symptoms) while preserving CNS M1/M4 agonism. This dual-component approach represents a paradigm shift away from dopamine D2 antagonism.
Compare Xanomeline-Trospium →FDA-Approved Indications
- Schizophrenia in adults — the ONLY non-dopaminergic antipsychotic FDA-approved
What Sets This Drug Apart
- FIRST and ONLY non-dopaminergic antipsychotic FDA-approved — mechanism entirely novel, based on muscarinic M1/M4 agonism rather than D2 antagonism.
- Unique GI side effect profile driven by cholinergic agonism (nausea 19%, vomiting 15%, dyspepsia 18%), NOT metabolic/weight-related complications seen with dopaminergic drugs.
- ABSOLUTE requirement for fasting administration: food reduces trospium AUC by 85-90%. This strict dosing constraint is unique among antipsychotics and requires patient education and adherence support.
- ZERO QT prolongation at any clinically relevant dose — no QT risk whatsoever. Major safety advantage vs lumateperone, aripiprazole, and other SGAs. No cardiac monitoring required.
- Multiple absolute contraindications unusual for an antipsychotic: urinary retention, moderate/severe hepatic impairment, gastric retention, untreated narrow-angle glaucoma.
- Absent metabolic syndrome, weight gain, sexual dysfunction, and tardive dyskinesia risk — non-dopaminergic mechanism eliminates D2-mediated metabolic and motor complications.